Download pdf
Utilizing Gene Editing to Explore the Function of the MYC Gene in Chronic Myelogenous Leukemia and Human Non-Small Cell Lung Cancer
- 1 Shanghai World Foreign Language Academy, Shanghai, China
* Author to whom correspondence should be addressed.
Abstract
Chronic myelogenous leukemia (CML) and non-small cell lung cancer (NSCLC) are two common malignant tumors. Traditional treatments mainly include chemotherapy, radiotherapy, and bone marrow transplantation for CML. However, the low success rate of donor matching limits the widespread use of bone marrow transplants. The development of tumors is closely related to mutations or overexpression of multiple oncogenes, but their regulatory mechanisms and effective therapeutic strategies are still unclear. In recent years, the rapid development of gene editing technology, especially the CRISPR-Cas9 system, has provided new technical means for screening therapeutic targets for leukemia and lung cancer. This project utilizes the CRISPR-Cas9 system to knock out the MYC gene, which is considered a key oncogene in many human cancers. The first step of this project is to construct MYC gene knockout cell lines for CML and NSCLC, and to evaluate the effects on tumor cell proliferation and differentiation in vitro. It is expected that knocking out the MYC gene will significantly inhibit tumor cell proliferation and activate the expression of differentiation-related genes. This study will help reveal the role of the MYC gene in tumorigenesis and provide important theoretical support and potential clinical application value for targeted therapy of CML and NSCLC, further promoting the development of personalized precision medicine.
Keywords
Gene editing, chronic myelogenous leukemia, non-small cell lung cancer
[1]. Ahmadi, S. E., Rahimi, S., Zarandi, B., Chegeni, R. & Safa, M. MYC: a multipurpose oncogene with prognostic and therapeutic implications in blood malignancies. J Hematol Oncol 14, 121 (2021). https://doi.org:10.1186/s13045-021-01111-4
[2]. Dufort, D. & Nepveu, A. The human cut homeodomain protein represses transcription from the c-myc promoter. Mol Cell Biol 14, 4251-4257 (1994). https://doi.org:10.1128/mcb.14.6.4251-4257.1994
[3]. Carabet, L. A., Rennie, P. S. & Cherkasov, A. Therapeutic Inhibition of Myc in Cancer. Structural Bases and Computer-Aided Drug Discovery Approaches. Int J Mol Sci 20 (2018). https://doi.org:10.3390/ijms20010120
[4]. Ahmadi, S. E., Rahimi, S., Zarandi, B., Chegeni, R. & Safa, M. MYC: a multipurpose oncogene with prognostic and therapeutic implications in blood malignancies. Journal of hematology & oncology 14, 1-49 (2021).
[5]. Nowak, N., Kulma, A. & Gutowicz, J. Up-regulation of key glycolysis proteins in cancer development. Open Life Sciences 13, 569-581 (2018). https://doi.org:doi:10.1515/biol-2018-0068
[6]. Goetzman, E. S. & Prochownik, E. V. The Role for Myc in Coordinating Glycolysis, Oxidative Phosphorylation, Glutaminolysis, and Fatty Acid Metabolism in Normal and Neoplastic Tissues. Front Endocrinol (Lausanne) 9, 129 (2018). https://doi.org:10.3389/fendo.2018.00129
[7]. Kung, C. P. & Weber, J. D. It's Getting Complicated-A Fresh Look at p53-MDM2-ARF Triangle in Tumorigenesis and Cancer Therapy. Front Cell Dev Biol 10, 818744 (2022). https://doi.org:10.3389/fcell.2022.818744
[8]. Nirala, B. K. et al. MYC regulates CSF1 expression via microRNA 17/20a to modulate tumor-associated macrophages in osteosarcoma. JCI insight 8 (2023).
[9]. Meškytė, E. M., Keskas, S. & Ciribilli, Y. MYC as a multifaceted regulator of tumor microenvironment leading to metastasis. International Journal of Molecular Sciences 21, 7710 (2020).
[10]. Ran, F. A. et al. Genome engineering using the CRISPR-Cas9 system. Nature Protocols 8, 2281-2308 (2013). https://doi.org:10.1038/nprot.2013.143
Cite this article
Hao,R. (2025). Utilizing Gene Editing to Explore the Function of the MYC Gene in Chronic Myelogenous Leukemia and Human Non-Small Cell Lung Cancer. Theoretical and Natural Science,99,16-27.
Data availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
Disclaimer/Publisher's Note
The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of EWA Publishing and/or the editor(s). EWA Publishing and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
About volume
Volume title: Proceedings of the 5th International Conference on Biological Engineering and Medical Science
© 2024 by the author(s). Licensee EWA Publishing, Oxford, UK. This article is an open access article distributed under the terms and
conditions of the Creative Commons Attribution (CC BY) license. Authors who
publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons
Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this
series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published
version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial
publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and
during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See
Open access policy for details).